Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
108 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Burkitt Lymphoma - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Burkitt Lymphoma - Pipeline Review, H2 2015', provides an overview of the Burkitt Lymphoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Burkitt Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkitt Lymphoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Burkitt Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Burkitt Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Burkitt Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Burkitt Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Burkitt Lymphoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Burkitt Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Burkitt Lymphoma Overview 7 Therapeutics Development 8 Pipeline Products for Burkitt Lymphoma - Overview 8 Pipeline Products for Burkitt Lymphoma - Comparative Analysis 9 Burkitt Lymphoma - Therapeutics under Development by Companies 10 Burkitt Lymphoma - Therapeutics under Investigation by Universities/Institutes 11 Burkitt Lymphoma - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Burkitt Lymphoma - Products under Development by Companies 14 Burkitt Lymphoma - Products under Investigation by Universities/Institutes 15 Burkitt Lymphoma - Companies Involved in Therapeutics Development 16 AbbVie Inc. 16 AmpliMed Corporation (Inactive) 17 Arvinas, Inc. 18 AstraZeneca Plc 19 Constellation Pharmaceuticals, Inc. 20 Immunomedics, Inc. 21 Karyopharm Therapeutics, Inc. 22 Millennium Pharmaceuticals, Inc. 23 Seattle Genetics, Inc. 24 Theravectys SA 25 Burkitt Lymphoma - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 19-3s - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 20-3s - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 alisertib - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 ARV-825 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 AZD-6738 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 denintuzumab mafodotin - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 E1-3s - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 ibrutinib - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 imexon - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 ixazomib citrate - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Monoclonal Antibody Conjugated to Target CD20 for Leukemia and Burkitt Lymphoma - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 selinexor - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 SH-7129 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 SH-7133 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 SH-7139 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Small Molecules to Inhibit BET for Cancer - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Vaccine for EBV Associated Cancer - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Burkitt Lymphoma - Recent Pipeline Updates 72 Appendix 107 Methodology 107 Coverage 107 Secondary Research 107 Primary Research 107 Expert Panel Validation 107 Contact Us 107 Disclaimer 108
List of Tables
Number of Products under Development for Burkitt Lymphoma, H2 2015 8 Number of Products under Development for Burkitt Lymphoma - Comparative Analysis, H2 2015 9 Number of Products under Development by Companies, H2 2015 10 Number of Products under Investigation by Universities/Institutes, H2 2015 11 Comparative Analysis by Clinical Stage Development, H2 2015 12 Comparative Analysis by Early Stage Development, H2 2015 13 Products under Development by Companies, H2 2015 14 Products under Investigation by Universities/Institutes, H2 2015 15 Burkitt Lymphoma - Pipeline by AbbVie Inc., H2 2015 16 Burkitt Lymphoma - Pipeline by AmpliMed Corporation (Inactive), H2 2015 17 Burkitt Lymphoma - Pipeline by Arvinas, Inc., H2 2015 18 Burkitt Lymphoma - Pipeline by AstraZeneca Plc, H2 2015 19 Burkitt Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2015 20 Burkitt Lymphoma - Pipeline by Immunomedics, Inc., H2 2015 21 Burkitt Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 22 Burkitt Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 23 Burkitt Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2015 24 Burkitt Lymphoma - Pipeline by Theravectys SA, H2 2015 25 Assessment by Monotherapy Products, H2 2015 26 Number of Products by Stage and Target, H2 2015 28 Number of Products by Stage and Mechanism of Action, H2 2015 30 Number of Products by Stage and Route of Administration, H2 2015 32 Number of Products by Stage and Molecule Type, H2 2015 34 Burkitt Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015 72
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.